Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica

Volumn 97, Issue 10, 2012, Pages 1582-1585

  Schnittger, Susanne ^a   Bacher, Ulrike ^a,b   Eder, Christiane ^a   Dicker, Frank ^a   Alpermann, Tamara ^a   Grossmann, Vera ^a   Kohlmann, Alexander ^a   Kern, Wolfgang ^a   Haferlach, Claudia ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Chronic myelomonocytic leukemia; Diagnostic workflow; Molecular analyses; Mutation screening; Myeloproliferative neoplasms

Indexed keywords

BCR ABL PROTEIN; CBL PROTEIN; JANUS KINASE 2; TRANSCRIPTION FACTOR EZH2;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MOLECULAR DIAGNOSIS; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; THROMBOCYTHEMIA; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EXONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INFANT; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; WORKFLOW; YOUNG ADULT;

EID: 84867264111     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064683     Document Type: Article

References (20)

1. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-68.
2. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011208-14.
3. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
4. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-92.
5. Tefferi A, Pardanani A, Lim KH, Abdel- Wahab O, Lasho TL, Patel J, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905-11.
6. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-6.
7. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25(7):1200-2.
8. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-65.
9. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25(5):877-9.
10. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118 (14):3932-41.
11. Swerdlow S, Campo E, Lee Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Lyon: IARC Press, 2008.
12. Schnittger S, Bacher U, Kern W, Schröder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia. 2006;20(12):2195-7.
13. Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica. 2009;94(3):414-8.
14. Schnittger S, Bacher U, Haferlach C, Dengler R, Kröber A, Kern W, et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia. 2008;22(2): 453-5.
15. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8(1):186-9.
16. Tefferi A, Noel P, Hanson CA. Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2011;13(5):461-6.
17. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363(12): 1189-90.
18. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24(10):1713-8.
19. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.
20. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012 Aug 23. [Epub ahead of print]